Summit on Cancer Health Disparities (SCHD25)

Seattle, WA US
April 25, 2025 to April 27, 2025

The Summit on Cancer Health Disparities 2025 (SCHD25) is a premier annual event focused on addressing cancer health disparities. The conference serves to bridge research and practice, offering practical strategies to improve cancer care delivery and outcomes. SCHD25 will unite oncology professionals, researchers, policymakers, and other stakeholders looking to address factors contributing to cancer health disparities with evidence-based interventions.

The conference features lectures, panel discussions, debates, and case-based discussions led by leaders in cancer care. Advances in implementation science and artificial intelligence will provide additional insights into how barriers to cancer care can be alleviated. The event includes oral and poster abstract sessions.  

As an accredited CME activity, SCHD25 promotes interdisciplinary interactions and partnerships, equipping participants with tools to translate research into actionable strategies for diverse healthcare settings.

Target Audience

  • Oncologists
  • Nurse Practitioners
  • Physician Assistants
  • Nurses
  • Pharmacists
  • Fellows/Residents
  • Researchers
  • Others interested in cancer disparities

Organizing Committee 

Program Director:

  • Binay Shah, MD, MHA - Binaytara

Conference Co-Chairs:

  • Ana María López, MD, MPH - Sidney Kimmel Cancer Center, Thomas Jefferson University
  • David Aboulafia, MD - Virginia Mason Medical Center

Planning Committee Members:

  • Manisha Bhattacharya, MD, MBA - University of Pittsburgh Medical Center
  • Jorge E. Cortes, MD  -   Georgia Cancer Center at Augusta University
  • Don S. Dizon, MD - Lifespan Cancer Institute, Rhode Island Hospital and The Warren Alpert Medical School of Brown University
  • Manish Kohli, MD - Huntsman Cancer Institute, University of Utah
  • Mark Pegram, MD - Stanford University
  • Martha Pritchett Mims, MD, PhD - Baylor College of Medicine
  • Prakash C. Neupane, MBBS - University of Kansas Medical Center
  • Jerald Radich, MD - Fred Hutchinson Cancer Center and University of Washington
  • Rayne Helen Rouce, MD - Baylor College of Medicine and Texas Children's
  • Gregory Vidal, MD, PhD - West Cancer Center
  • Siddhartha Yadav, MBBS, MD - Mayo Clinic

Abstract Committee Co-Chairs:

  • Martha Pritchett Mims, MD, PhD - Baylor College of Medicine
  • Gregory Vidal, MD, PhD - West Cancer Center

Abstract Committee Members:

  • Ursa Brown-Glaberman, MD - University of New Mexico Comprehensive Cancer Center
  • Shipra Gandhi, MD - Roswell Park Comprehensive Cancer Center
  • Charles Jiang, MD - UT Southwestern Medical Center
  • Darya Kizub, MD - MD Anderson Cancer Center
  • Don S. Dizon, MD - Lifespan Cancer Institute, Rhode Island Hospital and The Warren Alpert Medical School of Brown University
  • Manish Kohli, MD - Huntsman Cancer Institute, University of Utah
  • Cecilia Yeung, MD - Fred Hutchinson Cancer Center and University of Washington

Media and Publications Committee Co-Chairs: 

  • Arya Mariam Roy, MD - The Ohio State University
  • Matt Lambert - Binaytara

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Identify and critically analyze the complex interplay of factors contributing to cancer health disparities across diverse populations.
  • Apply implementation science principles to develop and implement evidence-based interventions to address cancer disparities within their specific contexts.
  • Evaluate the effectiveness of various strategies for improving cancer outcomes among underserved populations, including patient navigation, community engagement, and policy advocacy.
  • Collaborate with interdisciplinary teams to develop and implement comprehensive cancer control plans that address the unique needs of marginalized communities, and advocate for policies and system changes to reduce cancer health disparities and promote health equity.
  • Review the impact of AI on access to cancer care.

Parking 

Hotel offers daily valet parking at $58.

Course summary
Available credit: 
  • 16.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 16.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-013-H01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 16.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 16.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 16.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 16.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 16.50 Contact Hours.
Course opens: 
07/08/2024
Course expires: 
07/28/2025
Event starts: 
04/25/2025 - 8:00am PDT
Event ends: 
04/27/2025 - 12:00pm PDT
Cost:
$350.00
Add to calendar: 

DAY 1 - APRIL 25, 2025

All times are listed in Pacific Time (PT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

08:00 AM – 08:15 AM  Welcome and Opening Remarks

08:15 AM – 09:15 AM  Session 1: Evolving the Landscape Towards Cancer Health Equity

Session Chairs: David Aboulafia, MD & Jessica Y. Islam, PhD, MPH

08:15 AM – 08:35 AM  Community based research in BIPOC populations: Lessons learned from COVID - Michele Peake Andrasik, PhD, EdM 

08:35 AM – 08:50 AM  Racial/Ethnic Disparities: Discrimination’s Impact on Health-Related Quality of Life-An All of Us Cancer Survivors - Albert J. Farias, PhD, MPH

08:50 AM – 09:05 AM  Racism as a Public Health Crisis - Marlene Camacho-Rivera, SCD, MS, MPH

09:05 AM – 09:15 AM  Panel Discussion

09:15 AM – 10:15 AM  Session 2: Root Causes of Cancer Disparities: An Intersectional Perspective

Session Chair: Rayne Helen Rouce, MD

09:15 AM – 09:35 AM  Keynote Address - Eneida Nemecek, MD, MS, MBA

09:35 AM – 10:15 AM  Panel Discussion - Banu Symington, MD; Mohamed Sorror, MD, MSc; Patricia Hirschberg-Sines, BSN, RN, BMTCN; Analisa Marotta

10:15 AM – 10:30 AM  Break & Exhibits

10:30 AM – 12:00 PM  Session 3: Breakout Sessions

10:30 AM – 11:15 AM  Breakout Session A1: Smoking Related Cancer Disparities

Session Chair: Lei Deng, MD

10:30 AM – 10:45 AM  Opening Talk - Lauren Shih, MD

10:45 AM – 11:15 AM  Panel Discussion - Siddhartha Devarakonda, MD; Andrea Veatch, MD

10:30 AM – 11:15 AM  Breakout Session A2: ctDNA in Current and Future Practice of GI Oncology

Session Chair: Marianne Dubard-Gault, MD, MS 

10:30 AM – 10:45 AM  ctDNA in the management and surveillance of colorectal cancers - Stacey Cohen, MD

10:45 AM – 11:15 AM  Panel Discussion - Gautam Mankaney, MD; Vlad Simianu, MD, MPH; Brianna Van Den Adel, MS, CGC

11:15 AM – 12:00 PM  Breakout Session B: Access to Cellular Therapy

Session Chair: Mazyar Shadman, MD, MPH

11:15 AM – 11:30 AM  Opening Talk - Folashade Otegbeye, MBChB, MPH

11:30 AM – 12:00 PM  Panel Discussion - Mohamed Sorror, MD MSc; Melinda Biernacki, MD; Lisa Getzendaner PA-C, MHS

12:00 PM – 01:00 PM  Lunch & Exhibits

01:00 PM – 02:00 PM  Session 4: Introduction to Implementation Science: Bridging the Gap Between Research and Practice

Session Chairs: Siddhartha Yadav, MBBS, MD & Catherine Duggan, PhD

01:00 PM – 01:20 PM  Implementation Science in Cancer Prevention and Early Detection in Global Oncology Settings - Lifang Hou, MD, PhD

01:20 PM – 02:00 PM  Panel Discussion - Salene M. W. Jones, PhD; Katrina Ortblad, ScD, MPH

02:00 PM – 03:00 PM  Session 5: Successful Implementation of Equity-Enhancing Interventions

Session Chairs: Gregory Vidal, MD, PhD & Manisha Bhattacharya, MD, MBA

02:00 PM – 02:20 PM  Pragmatica Trial - Konstantin H. Dragnev, MD

02:20 PM – 02:40 PM  Development and Application of a Financial Toxicity Tool - Maria Lizette Rangel, DrPh, MPH, CHWI

02:40 PM – 03:00 PM  Addressing Breast Cancer Equity Through Virtual Community Oncology Navigation and Engagement (vCONET) - Manisha Salinas, PhD

03:00 PM – 03:15 PM  Break & Exhibits

03:15 PM – 04:15 PM  Session 6: Overcoming Barriers to Implementation

Session Chairs: Gregory Vidal, MD, PhD & Sonya Reid, MD, MPH

03:15 PM – 03:30 PM  Barriers and Facilitators to Clinical Trial Diversity - Yara Abdou, MD

03:30 PM – 03:45 PM  Implementation of Precision Medicine and its Impact on Access to Care and Health Equity Disparity - Neha Jain, PhD

03:45 PM – 04:00 PM  Barriers to Implementing Evidence-Based Practices in Diverse Communities - Marvella Ford, PhD

04:00 PM – 04:15 PM  Panel Discussion 

 

DAY 2 - APRIL 26, 2025

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

08:00 AM – 09:00 AM  Session 7: Leveraging Technology and AI to Support Cancer Health Equity

Session Chairs: Kingsley Ndoh, MD, MPH & John Kang, MD, PhD

08:00 AM – 08:20 AM  Keynote Address - Chung II Wi, MD

08:20 AM – 08:40 AM  Emerging Technology to Support Cancer Health Equity - Hoifung Poon, PhD

08:40 AM – 09:00 AM  Panel Discussion - Helen Storey, PhD

09:00 AM – 10:00 AM  Session 8: Community Outreach and Engagement: What is the Evidence of Impact?

Session Chair: Don S. Dizon, MD, FACP, FASCO

09:00 AM – 09:10 AM  Engagement with Cancer Survivors and Communities at Risk - Memnun Seven, RN, MSN, PhD, FAAN

09:10 AM – 09:20 AM  Effective Utilization of Community Advisory Boards - Andrew Sussman, PhD, MCRP

09:20 AM – 09:30 AM  Engagement in a New Media Environment - Vida Henderson, PhD, PharmD, MPH, MFA

09:30 AM – 10:00 AM  Panel Discussion

10:00 AM – 10:15 AM  Break & Exhibits

10:15 AM – 11:45 AM  Session 9: Breakout Sessions

10:15 AM – 11:00 AM  Breakout Session C: Links to Care - Real World Experience: Building Bridges Between Health Systems

Session Chairs: Joseph Rosales, MD & Carilla Wallin, MBA

10:15 AM – 10:30 AM  Case Presentation - Camille Biggins & Brendan Lo, MPH

10:30 AM – 11:00 AM  Panel Discussion - Cindee DeWitt; Gabrielle Flowers

11:00 AM – 11:45 AM  Breakout Session D: Global Oncology - Innovative Solutions to Cancer Care Accessibility

Session Chair: Shailender Bhatia, MD

11:00 AM – 11:05 AM  Session Overview and Introductions - Shailender Bhatia, MD

11:05 AM – 11:10 AM  Innovations in Molecular Diagnostics - Vivian Oehler, MD

11:10 AM – 11:15 AM  Considering Global Standardization in Radiotherapy - Benjamin Li, MD, MBA

11:15 AM – 11:20 AM  AFFORD-IO - A Phase 2 Trial of Low-Dose, Reduced-Frequency Nivolumab in Uganda - Shailender Bhatia, MD

11:20 AM – 11:45 AM  Panel Discussion

10:15 AM – 11:45 AM  Oral Abstract Presentations

11:45 AM – 12:45 PM  Lunch & Exhibits

12:00 PM – 12:45 PM  Product Theater by Johnson & Johnson in Cove Room

12:45 PM – 01:45 PM  Session 10: Measuring and Evaluating Equity-Enhancing Interventions

Session Chair: Ana María López, MD, MPH, MACP

12:45 PM – 01:15 PM  Keynote Address -  

01:15 PM – 01:45 PM  Panel Discussion - Bessie Young MD, MPH, FACP, FASN; Lesley Kailani Glenn

01:45 PM – 02:45 PM  Session 11: Building Sustainable Partnerships for Cancer Health Equity

Session Chairs: Anu Agrawal, MD & Corey Casper, MD, MPH

01:45 PM – 02:05 PM  Keynote Speech - Anu Agrawal, MD 

02:05 PM – 02:45 PM  Panel Discussion - Kingsley Ndoh, MD, MPH; Ashwani Rajput, MD

02:45 PM – 03:00 PM  Break & Exhibits

03:00 PM – 04:15 PM  Session 12: Global Oncology

Session Chair: Prakash C. Neupane, MBBS

03:00 PM – 03:15 PM  Sustainable Care Models in Low and Middle Income Countries - Corey Casper, MD, MPH

03:15 PM – 03:30 PM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Siddhartha Yadav, MBBS, MD

03:30 PM – 04:15 PM  Panel Discussion - Steven Kussick, MD, PhD; Dan Milner, MD, MSc, MBA

06:00 PM – 08:30 PM  Binaytara Annual Gala

Register Here - https://binayfoundation.ejoinme.org/2025gala

 

DAY 3 - APRIL 27, 2025

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

07:00 AM – 08:30 AM  Poster Abstract Session

**This is a non-CME activity**

08:30 AM – 09:15 AM  Session 13: The Role of Policy in Supporting Cancer Health Equity

Session Chair: Willie Underwood III, MD, MSc, MPH

08:30 AM – 08:45 AM  Keynote Speech - Willie Underwood III, MD, MSc, MPH

08:45 AM – 09:15 AM  Panel Discussion - Archie L. Rich II

09:15 AM – 10:00 AM  Session 14: Developing Effective Advocacy Campaigns

Session Chair: Dan Milner, MD, MSc, MBA

09:15 AM – 09:30 AM  Keynote Speech - Lisa Lacasse

09:30 AM – 10:00 AM  Panel Discussion - Tricia Johnson; Jourdan Cruz, MSc, MSW, LICSW; Sara Martin 

10:00 AM – 10:15 AM  Break & Exhibits

10:15 AM – 12:00 PM  Session 15: Debate - Crisis in Care: Can the U.S. Find a Sustainable Model for Affordable Healthcare?

Moderators: Anne-Marie Green

Panelists: Alan Balch, PhD; E. Anders Kolb, MD; Larry Kessler, ScD

12:00 PM  Adjourn

Bell Harbor International Conference Center
2211 Alaskan Wy
Seattle, WA 98121
United States

Parking 

Hotel offers daily valet parking at $58.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Anu Agrawal, M.D.

has a financial relationship (Professional Services) with Beam Therapeutics ;.
has a financial relationship (Professional Services) with yMabs Therapeutics, LLC;.

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.

Carilla Curtiss Wallin, Masters of Business Administration

has no relevant financial relationships to disclose at this time.

Lei Deng, MD

has a financial relationship (Travel) with Merck;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.
has a financial relationship (Travel) with MJH Life Sciences;.

Marianne Dubard-Gault, MD, MS

has no relevant financial relationships to disclose at this time.

Catherine Duggan

has no relevant financial relationships to disclose at this time.

Danny Milner, Jr, MD, MSc, MBA

has no relevant financial relationships to disclose at this time.

Sonya Reid, MD, MPH

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Daiichi Sankyo;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Astra Zeneca;.

Mazyar Shadman, MD, MPH

has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Stock Options) with Koi Biotherapeutics;.
has a financial relationship (Professional Services) with Fate therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Vincerx ;.
has a financial relationship (Professional Services) with Eli Lily ;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma ;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with Mustang Bio ;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Repare Therapeutics;.
has a financial relationship (Other) with Astrazenca ;.
has a financial relationship (Other) with Astrazeneca ;.
Speaker/Topic Presenter(s)

Yara Abdou, MD

has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pfizer;.

Michele Andrasik, PhD, EdM, MA, MS

has no relevant financial relationships to disclose at this time.

Melinda Biernacki

has a financial relationship (Employment) with Outpace Bio;.

Camille Biggins, MHA

has no relevant financial relationships to disclose at this time.

Stacey Cohen

has a financial relationship (Independent contractor) with Delcath;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Agenus;.
has a financial relationship (Independent contractor) with Guardant;.
has a financial relationship (Independent contractor) with Exact Sciences;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Taiho;.
has a financial relationship (Travel) with Biomea;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Regeneron;.

Jourdan Cruz, MSc, MSW, LICSW

has no relevant financial relationships to disclose at this time.

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Eli Lilly;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Apollomics;.
has a financial relationship (Other) with Jazz;.
has a financial relationship (Other) with Daiichi-Sankyo;.

Cindee DeWitt

has no relevant financial relationships to disclose at this time.

Konstantin Dragnev

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Conjupro;.
has a financial relationship (Grant Or Contract) with Eli Lilly;.
has a financial relationship (Grant Or Contract) with Henlius;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Molecular Templates;.

Albert Farias, PhD, MPH

has no relevant financial relationships to disclose at this time.

Gabrielle Flowers, BS

has no relevant financial relationships to disclose at this time.

Marvella Ford, PhD, MS, MSW

has no relevant financial relationships to disclose at this time.

Lisa Getzendaner, PA-C, MHS

has a financial relationship (Independent contractor) with Kite Pharmaceuticals;.

Lesley Glenn, BS

has no relevant financial relationships to disclose at this time.

Patricia Hirschberg-Sines, DNP, RN, BMTCN

has no relevant financial relationships to disclose at this time.

Lifang Hou

has no relevant financial relationships to disclose at this time.

Neha Jain

has a financial relationship (Employment) with OneOncology;.
has a financial relationship (Other) with J&J;.

Tricia Johsnon

has no relevant financial relationships to disclose at this time.

Salene Jones, PhD, MA, LP

has no relevant financial relationships to disclose at this time.

Edward Kolb, MD

has no relevant financial relationships to disclose at this time.

Steven Kussick, MD, PhD

has a financial relationship (Professional Services) with Beckman Coulter Life Sciences;.
has a financial relationship (Employment) with Phenopath, A Quest Diagnostics Company;.

Lisa Lacasse, MBA

has no relevant financial relationships to disclose at this time.

Benjamin Li, MD, MBA

has no relevant financial relationships to disclose at this time.

Brendan Lo, MPH

has no relevant financial relationships to disclose at this time.

Gautam Mankaney, MD

has no relevant financial relationships to disclose at this time.

Analisa Marotta

has no relevant financial relationships to disclose at this time.

Sara Martin

has a financial relationship (Employment) with Bristol Myers Squibb;.

Eneida Nemecek, MD, MS, MBA

has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Mesoblast;.
has a financial relationship (Independent contractor) with Medexus;.

Vivian Oehler

has a financial relationship (Grant Or Contract) with Pfizer, Inc;.
has a financial relationship (Other) with Takeda Pharmaceuticals;.
has a financial relationship (Other) with Terns Phamaceuticals;.
has a financial relationship (Other) with Ascentage Pharma;.
has a financial relationship (Other) with Novartis;.

Katrina Ortblad, ScD, MPH

has no relevant financial relationships to disclose at this time.

Folashade Otegbeye, MBChB, MPH

has no relevant financial relationships to disclose at this time.

Ashwani Rajput

has no relevant financial relationships to disclose at this time.

Lizette Rangel, DrPH, MPH, CHWI

has no relevant financial relationships to disclose at this time.

Memnun Seven, RN. MSN, PhD, FAAN

has no relevant financial relationships to disclose at this time.

Lauren Shih, MD

has a financial relationship (Stock) with Exact Sciences;.
has a financial relationship (Grant Or Contract) with Bayer;.

Vlad Simianu, MD, MPH

has a financial relationship (Other) with BD Surgical;.

Mohamed Sorror

has a financial relationship (Professional Services) with JAZZ PHARMACEUTICALS CANADA;.

Helen Storey, MS PhD

has no relevant financial relationships to disclose at this time.

Andrew Sussman, PhD, MCRP

has no relevant financial relationships to disclose at this time.

Brianna Van den adel

has no relevant financial relationships to disclose at this time.

Chung-Il Wi, Medical Doctor

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Repare Therapeutics;.
has a financial relationship (Other) with Astrazenca ;.
has a financial relationship (Other) with Astrazeneca ;.
Planning committee(s)

Manisha Bhattacharya

has no relevant financial relationships to disclose at this time.

Ursa Brown-Glaberman, Associate Professor

has a financial relationship (Independent contractor) with SeaGen;.

Don Dizon, MD, FACP, FASCO

has a financial relationship (Professional Services) with Puma;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with Clovis;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Grant Or Contract) with BMS;.

Shipra Gandhi, MD, MS

has a financial relationship (Other) with Novartis;.
has a financial relationship (Professional Services) with Aptitude Health;.
has a financial relationship (Professional Services) with MedPage Today;.
has a financial relationship (Professional Services) with OncLive;.

Changchuan(Charles) Jiang, MD, MPH

has no relevant financial relationships to disclose at this time.

Manish Kohli

has a financial relationship (Travel) with Apollo Hospital Enterprise Limited;.
has a financial relationship (Travel) with Triomics;.
has a financial relationship (Professional Services) with Tempus Inc;.
has a financial relationship (Professional Services) with Janssen Scientific Affairs, LLC;.

Martha Mims

has a financial relationship (Stock) with Biogen IDEC;.
has a financial relationship (Stock) with Amgen;.

Arya Mariam Roy, MD

has no relevant financial relationships to disclose at this time.

Acknowledgement of Commercial Support

This activity is supported with an Independent Medical Education grant from Gilead Sciences.

Available Credit

  • 16.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 16.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-013-H01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 16.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 16.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 16.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 16.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 16.50 Contact Hours.

If you are interested in exhibiting at this meeting or purchasing a badge with your company at our discounted rate for exhibitors, please visit our exhibit page here - https://www.sponsorships.binayfoundation.org/SCHD25

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.